Rachel Klemovitch, Assistant Editor05.01.24
Vitestro has raised $22 million in funding for the commercialization of its robotic blood-drawing device in Europe and the US. This brings total funding to $50 million for grant funding and equity investments.
Sonder Capital and NYBC Ventures co-led funding with participation from Invest-NL, the European Innovation Council Fund, and existing private investors.
Vitestro combines artificial intelligence, robotics, and advanced imaging in its device to provide accurate and autonomous blood draws. This aims to reduce the need for manual handling and improve patient and clinician satisfaction.
"We are honored to continue working with Sonder Capital and proud to welcome NYBC Ventures, Invest-NL, and EIC Fund to the Vitestro team,” said Toon Overbeeke, Vitestro CEO and co-founder. “Early feedback from hospitals, staff, and patients has been overwhelmingly positive, and we are eager to quickly expand our reach and impact globally.”
Vitestro devices have been pre-ordered and are scheduled to be deployed at several European hospitals starting at the end of this year to help ease workloads and provide a more consistent, improved patient experience. The company is also currently leading the A.D.O.P.T. trial, the world’s largest evaluation of autonomous blood drawing devices.
"Vitestro’s revolutionary device is perfectly positioned to improve patient care and streamline operations for a medical laboratory market in crisis,” said Dr. Fred Moll, managing partner at Sonder Capital and the co-founder of Intuitive Surgical. “As turnover and departures accelerate, staff are overwhelmed and labs are challenged to deliver timely test results and satisfactory care. We are excited by Vitestro’s progress and believe they will modernize the blood draw experience.”
Vitestro hopes to receive CE approval for the device by the end of 2024.
Sonder Capital and NYBC Ventures co-led funding with participation from Invest-NL, the European Innovation Council Fund, and existing private investors.
Vitestro combines artificial intelligence, robotics, and advanced imaging in its device to provide accurate and autonomous blood draws. This aims to reduce the need for manual handling and improve patient and clinician satisfaction.
"We are honored to continue working with Sonder Capital and proud to welcome NYBC Ventures, Invest-NL, and EIC Fund to the Vitestro team,” said Toon Overbeeke, Vitestro CEO and co-founder. “Early feedback from hospitals, staff, and patients has been overwhelmingly positive, and we are eager to quickly expand our reach and impact globally.”
Vitestro devices have been pre-ordered and are scheduled to be deployed at several European hospitals starting at the end of this year to help ease workloads and provide a more consistent, improved patient experience. The company is also currently leading the A.D.O.P.T. trial, the world’s largest evaluation of autonomous blood drawing devices.
"Vitestro’s revolutionary device is perfectly positioned to improve patient care and streamline operations for a medical laboratory market in crisis,” said Dr. Fred Moll, managing partner at Sonder Capital and the co-founder of Intuitive Surgical. “As turnover and departures accelerate, staff are overwhelmed and labs are challenged to deliver timely test results and satisfactory care. We are excited by Vitestro’s progress and believe they will modernize the blood draw experience.”
Vitestro hopes to receive CE approval for the device by the end of 2024.